The recognition of LY6E as a promising focus for cancer treatment has sparked considerable investigation . Multiple protein programs are being explored with the aim of specifically inhibiting LY6E's function and promoting an antitumor outcome in patients affected with various tumors. Hurdles remain in optimizing therapeutic targeting and mitigating